QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Deal would value the Baxter spinoff at more than $4 billionhttps://www.wsj.com/finance/investing/carlyle-in-advanced-talks-to-a...

 evercore-isi-group-maintains-outperform-on-baxter-intl-lowers-price-target-to-45

Evercore ISI Group analyst Vijay Kumar maintains Baxter Intl (NYSE:BAX) with a Outperform and lowers the price target from $...

 goldman-sachs-initiates-coverage-on-baxter-intl-with-neutral-rating-announces-price-target-of-36

Goldman Sachs analyst David Roman initiates coverage on Baxter Intl (NYSE:BAX) with a Neutral rating and announces Price Tar...

 citigroup-maintains-neutral-on-baxter-intl-lowers-price-target-to-38

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:BAX) with a Neutral and lowers the price target from $44 to $38.

 fresenius-ses-future-with-dialysis-company-unclear-investors-seek-answers

Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite hol...

 fda-approves-baxters-clinolipid-neonatal-and-pediatric-indication

Clinolipid provides calories and essential fatty acids for parenteral nutritionExpanded indication demonstrates Baxter's co...

 td-cowen-downgrades-baxter-intl-to-hold-announces-40-price-target

TD Cowen analyst Joshua Jennings downgrades Baxter Intl (NYSE:BAX) from Buy to Hold and announces $40 price target.

 why-is-medical-device-maker-baxter-stock-trading-lower-on-thursday

Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a repo...

 baxter-intl-q1-2024-adj-eps-065-beats-061-estimate-sales-3590b-beat-3553b-estimate

Baxter Intl (NYSE:BAX) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.61 by 6.5...

 baxter-expands-pharmaceuticals-portfolio-with-five-injectable-products-in-us

Five new launches reinforce Baxter's focus on differentiated products and enhance the company's Pharmaceuticals portfol...